The specter of generic rivalry has long loomed above copyright’s famous drug, Sildenafil, sparking questions about the future of connected pharmaceutical investments. While first periods saw substantial profits, the intellectual property lapse has allowed the door for less expensive copies, possibly reducing revenue and posing a real risk for st… Read More